The medication is self-injected subcutaneously once a week, and any questions about dosing or side effects are handled through messages with the provider
Use of a GLP-1glucagon-like peptide-1 receptor agonistwas first approved by the FDA in 2005 for patients with type-2 diabetes, but in 2014 also received FDA approval for obesity treatment
Health Canada is warning the public of seized unauthorized injectable peptide drugs from Canada Peptide
Ami Patel , Rosa Isela Gallagher, Barbara Merritt, Lucia Pastore, Joel Sennesh, Kirsten Edmiston, Emanuel F
Am J Dis Child 80: 390-403, 1950
Most patients experience peak constipation during the first 24 weeks, with significant improvement by week 68 as your gut microbiome adapts